The telehealth company Hims & Hers has made waves for its Super Bowl ad that plugged its lower-priced form of injectable ...

The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...

Andrew Dudum; Chairman of the Board, Chief Executive Officer; Hims & Hers Health Inc Oluyemi Okupe; Chief Financial Officer; Hims & Hers Health Inc Good afternoon, ladies and gentlemen, and thank you ...

Shares of Hims & Hers Health tumbled 18% premarket on Tuesday as Wall Street analysts questioned the telehealth provider's ...

Investing.com - Hims&Hers (NYSE:HIMS) said on Monday that it may stop selling legal copies of a popular weight-loss drug made by Denmark's Novo Nordisk (NYSE:NVO), sending shares in the U.S.

Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to ...

A series of important developments in the healthcare sector includes Medtronic adapting to tariff threats, Hims & Hers facing ...

Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) will be reporting earnings tomorrow after the bell. Here’s ...

Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much ...

Ahead of whatever Jensen Huang & Co. announces, let's look at another highflying stock: Costco Wholesale (COST). Christopher Bloomstran, the president and chief investment officer St. Louis-based ...

Citi raised the firm’s price target on Hims & Hers to $27 from $25 and keeps a Sell rating on the shares post the Q4 report. The focus on ...

Hims & Hers projects $725M in GLP-1 weight loss revenue for 2025, a 3.2x increase from 2024. Read why I upgrade HIMS stock ...